HOLLISTON, Mass., May 14, 2014 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of equipment, instruments and solutions to advance life science, will present at the SeeThruEquity Third Annual Microcap Investor Conference in New York City on Wednesday, May 28, 2014.
Jeffrey Duchemin, President and Chief Executive Officer, and Robert Gagnon, Chief Financial Officer, will be reviewing the Company's business and growth strategy during their presentation, which will take place at 9:00 AM ET that day. Management will also be available to meet with members of the investment community during one-on-one sessions being held at the conference.
The presentation will be webcast live, archived for seven days, and available at the following link: http://wsw.com/webcast/seethru7/hbio
Members of the investment community interested in meeting with management that day can contact their representative at SeeThruEquity, or Tom Caden of DGI at 212-825-3210.
About Harvard Bioscience
Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of equipment, instruments and solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, catalogs, websites, and through distributors including GE Healthcare, Thermo Fisher Scientific Inc., VWR and other specialized distributors. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France and Canada. For more information, please visit our website at www.harvardbioscience.com.
Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, the anticipated savings, cost reductions, restructuring charges and reinvestment amounts. These statements involve risks and uncertainties, including among other things, market conditions and other factors that may cause the actual results to differ materially from the statements set forth in this press release. The forward-looking statements in this press release speak only as of the date of this press release. Harvard Bioscience expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.
The Harvard Bioscience logo is available at: http://www.globenewswire.com/newsroom/prs/?pkgid=23828
For investor inquiries, please call (508) 893-8066. Press releases may be found on our web site.
CONTACT: Harvard Bioscience Jeffrey A. Duchemin President and Chief Executive Officer Tel: (508) 893-8999 Investor and Public Relations: Dian Griesel Int'l. Cheryl Schneider/Susan Forman (212) 825-3210
Source:Harvard Bioscience, Inc.